Biosimilars: What you should know, now and in the future
For those keeping an eye on rising health care costs in the US, the development of biosimilar drug therapies has held the promise and potential to tamp down skyrocketing costs for specialty medications. However, the road to widespread adoption of biosimilars has proven to be a rougher ride than expected.
What could biosimilars do for the specialty drug industry, and what are the obstacles? What does the future hold for biosimilar drug therapies?
This new white paper sheds light on the difference between biologics and conventional drugs, the requirements biosimilars have to meet as “generics”, the state of the US marketing in biosimilars, and how regulations and even court rulings may influence the future of these drugs.
Download the full white paper here: Biosimilar_WP_0318_UNB